clinical trial · NCT03345823
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433
AbbVie·phase3·active not recruiting·n = 747
Crohn's DiseaseUpadacitinibPlacebo for Upadacitinib
brief summary
A multicenter study to evaluate the efficacy and safety of maintenance and long-term treatment administration of upadacitinib, an orally administered Janus kinase 1 inhibitor, in adult participants with Crohn's Disease.
started
Mar 21, 2018
primary completion
Sep 1, 2027
completion
Sep 1, 2027
last updated
Apr 9, 2026
official title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects With Crohn's Disease Who Completed the Studies M14-431 or M14-433
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol